Valneva’s strategy stems from its vision to contribute to a world in which no one dies or suffers from a vaccine-preventable disease. We aim to become the leading specialty vaccine company. The Company’s strategy is based on an integrated business model that has a unique risk profile and significant potential for value creation.


Growing mid-term product sales revenues to ~ €200 million

  • Valneva’s commercial business continues to grow and the Company aims to add products to its commercial portfolio, leveraging its commercial and industrial infrastructure.


Investing in innovative R&D programs to meet unmet medical needs

  • Valneva’s R&D team is committed to developing vaccine candidates in areas of major unmet medical need and providing innovative preventative solutions for the benefit of both people and society.
  • Valneva’s current lead R&D assets include the only clinical-stage vaccine against Lyme disease and a single-shot vaccine against chikungunya. As those unique assets progress through late-stage development towards market, Valneva expects to increase R&D investment significantly in the coming years.


Collaboration is often key to success in research and biotechnology.

  • Valneva collaborates with the world’s leading pharmaceutical and biotech companies, as well as research institutes.
  • We are continuously seeking new partners to develop innovative, life-changing vaccines.